Dianthus Therapeutics, Inc. (DNTH)
Nasdaq · Healthcare · Biotechnology
$88.04−0.19%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $4.9B
- 52-week range
- $32.22 – $117.88
- 52-week change
- +154.21%
- EPS (trailing)
- −$4.24
- Analyst rating
- 1.1 Strong buy
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Revenue
- $2.0M (−67.35%)
- Net income
- −$162M
- Operating margin
- −8739.2%
- Diluted EPS
- −$4.20
From the company’s annual report on SEC EDGAR.
About Dianthus Therapeutics, Inc.
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Headquarters: New York, United States · 92 employees · dianthustx.com